T. Rowe Price Associates’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $303K | Buy |
23,273
+3,152
| +16% | +$41K | ﹤0.01% | 2520 |
|
|
2025
Q1 | $214K | Buy |
20,121
+1,103
| +6% | +$11.7K | ﹤0.01% | 2597 |
|
|
2024
Q4 | $323K | Buy |
19,018
+1,279
| +7% | +$21.7K | ﹤0.01% | 2469 |
|
|
2024
Q3 | $412K | Buy |
17,739
+122
| +0.7% | +$2.83K | ﹤0.01% | 2334 |
|
|
2024
Q2 | $429K | Buy |
17,617
+613
| +4% | +$14.9K | ﹤0.01% | 2249 |
|
|
2024
Q1 | $575K | Buy |
17,004
+922
| +6% | +$31.2K | ﹤0.01% | 2153 |
|
|
2023
Q4 | $508K | Buy |
16,082
+360
| +2% | +$11.4K | ﹤0.01% | 2160 |
|
|
2023
Q3 | $402K | Sell |
15,722
-3,535
| -18% | -$90.4K | ﹤0.01% | 2211 |
|
|
2023
Q2 | $553K | Sell |
19,257
-617
| -3% | -$17.7K | ﹤0.01% | 2074 |
|
|
2023
Q1 | $477K | Buy |
19,874
+105
| +0.5% | +$2.52K | ﹤0.01% | 2126 |
|
|
2022
Q4 | $335K | Buy |
19,769
+1,522
| +8% | +$25.8K | ﹤0.01% | 2327 |
|
|
2022
Q3 | $271K | Buy |
18,247
+1,515
| +9% | +$22.5K | ﹤0.01% | 2419 |
|
|
2022
Q2 | $263K | Buy |
16,732
+410
| +3% | +$6.45K | ﹤0.01% | 2489 |
|
|
2022
Q1 | $440K | Buy |
16,322
+1,283
| +9% | +$34.6K | ﹤0.01% | 2386 |
|
|
2021
Q4 | $557K | Buy |
15,039
+298
| +2% | +$11K | ﹤0.01% | 2333 |
|
|
2021
Q3 | $704K | Sell |
14,741
-119,000
| -89% | -$5.68M | ﹤0.01% | 2207 |
|
|
2021
Q2 | $4.53M | Sell |
133,741
-49,328
| -27% | -$1.67M | ﹤0.01% | 1519 |
|
|
2021
Q1 | $7.56M | Sell |
183,069
-1,239,110
| -87% | -$51.2M | ﹤0.01% | 1424 |
|
|
2020
Q4 | $61.7M | Buy |
1,422,179
+718,793
| +102% | +$31.2M | 0.01% | 880 |
|
|
2020
Q3 | $30.2M | Buy |
703,386
+185,549
| +36% | +$7.96M | ﹤0.01% | 1037 |
|
|
2020
Q2 | $24.2M | Buy |
+517,837
| New | +$24.2M | ﹤0.01% | 1094 |
|